Graft of cardiac progenitors in a pig model of right ventricular failure triggers myocardial epimorphosis, regeneration and protection of function

Lambert V[1], Deleris A[2], Tibourtine[2], F, Fouilloux[3,2] V, Martin, A[4], Bridge, P[5], Aries E[3], Benoist, D[5], Pucéat, M[2]

[1]Paediatric and Congenital Cardiology, Department of Cardiology, Institut Mutualiste Montsouris, Paris, France ; [2]INSERM C2VN, Aix-Marseille University, Marseille ; [3]Department of Pediatric Cardiac Surgery, Aix-Marseille University, Marseille, France.[4] Department of Congenital Cardiac Surgery, Bordeaux University, Pessac- Bordeaux, France Laboratoire Imagerie Interventionnelle Experimentale CERIMED, Marseille,[5] Liryc – the Electrophysiology and Heart Modelling Institute, Pessac-Bordeaux, France

Correspondence: michel.puceat@inserm.fr

The failure of diseased adult heart to regenerate is a major burden to our societies. Besides patients with ischemia and left ventricular dysfunction, progress in pediatric surgery to repair cardiac malformations has led to a growing population of now adult congenital heart diseases patients with right ventricular failure. In the absence of any efficient pharmacological therapy for these patients, cell therapy has turned out to be the only option to regenerate the RV myocardium.

In this study, we demonstrate that the adult pig with RV failure, a model of repaired tetralogy of Fallot, has the ability of regenerative epimorphosis.

Human embryonic stem cell-derived cardiac Nkx2.5+ progenitor cells were seeded in a collagen based patch to cover the whole pig failing RV. We report that these cells migrate within the myocardium while reversing the interstitial fibrosis. They then engraft and fully differentiate into fetal-like human myocytes within the myocardium. The graft triggers activation of macrophages and the reprogramming of surrounding pig myocytes into $Oct4^+$ /$Nanog^-$ blastemal-like cells. The reprogrammed myocytes re-differentiate and proliferate around human myocytes. Altogether, our findings reveal that mammalian hearts have the ability to undergo epimorphosis, the major process of endogenous regeneration that leads to a recovery of their contractile function.

Congenital heart diseases (CHD) are the major developmental diseases (*1*). Significant and continuous progress in pediatric surgery from the 1990's to repair cardiac malformations has greatly improved the survival of children who now constitutes a growing population of adult CHD patients. In this specific population, right ventricular (RV) dysfunction typically develops as a consequence of chronic pressure and/or volume overload which is secondary to the originally lifesaving surgical repair procedures (*2*). Then, these young adult patients with grown up congenital heart (GUCH) diseases are at high risk of heart failure, severe arrhythmias, valve disease, pulmonary hypertension, cancer and potentially early aging(*3, 4*), which constitutes a medical burden (*2, 5*). Since more than 50% of GUCH patients have a risk of heart failure at 30 years old (*6*), RV failure makes the long-term follow-up of CHD a challenging medical issue.

The RV is thin, features a gene profile different from the LV and a maladaptive metabolic response to afterload (*7*), making it less equipped than LV to respond to overload. Furthermore, therapeutic options for this disease remain poorly investigated(*5*) and conventional therapeutic pharmacological approaches for these patients are often disappointing (*8*). In the long run, if the repair of causal myocardial lesions does not allow for an improvement in function, or if RV is a single ventricular heart such as in the hypoplastic left heart syndrome, organ transplantation is the only remaining option for these young patients. The difficulty and time to obtain heart grafts because of shortage of donors as well as the risk of such a heavy surgery for these young patients often severely affected(*9*) urgently calls for the search for alternative therapeutic pathways. Despite challenges which still need to be met, regenerative medicine still appears to be a powerful approach to prevent and treat terminal heart failure and its consequences (*10*).

Clinical trials of cell therapy for congenital heart disease are still rare (*11, 12*). The cell and molecular mechanisms as well as long term effects of that approach remained furthermore unclear.

The aims of our study performed on a large animal model of CHD was to evaluate the therapeutic potential of an epicardial delivery of human embryonic stem cells-derived cardiac progenitor cells (CPC) in a porcine model of chronic overloaded RV dysfunction (*13*) and to uncover the cellular and molecular mechanisms underlying the action of grafted cells.

To test the therapeutic effect of the graft of CPC, we performed heart surgery on 18 pigs in order to mimic the clinical situation of repaired TOF (*13*). Four animals died during the study: three from the sham group (one from severe cardiac failure, two featured

ventricular fibrillations), one from the control group (infection) before the end of the follow-up, and they were excluded from the final analysis. All remaining animals (n=6-8/group) gained weight and did not feature any clinical signs of heart failure. Age, weight, body length, and body surface area were similar in all groups at each stage (Fig. S1, Table 1). The time between the surgery and the delivery of epicardial patches was similar between CPC seeded patch and cell-free groups (206.0 ± 24.8 *vs* 211.5 ± 40.7 days respectively) as well as the whole duration of the experiment (296.3±17.4 *vs* 292.8± 23.2 days respectively). No mortality was observed after cell delivery, or during the follow-up, and no adverse effects occurred. Immunosuppression was well tolerated. In the post cell therapy period, all animals gained weight (Fig S1B, Table 1) and did not feature any clinical signs of either heart failure or immune rejection.

CPC were generated from the human embryonic stem cell line H9 genetically modified to express the ventricular myosin light chain 2 (MLC2v) fused to GFP (*14*) under the control of the cardiac α-actin promoter. Cells were sequentially challenged with a series of small molecules and growth factors (i.e, Wnt activator and BMP2 and then Wnt inhibitor and SHH) to direct them toward the fate of cardiac progenitors expressing NKX2.5 (Fig 1A)(*15*). Cells were then sorted with an anti-CD15 antibody directed against an antigen (SSEA-1) expressed at the surface of differentiated cells (*16*) (Fig. 1A).

When grafted within the collagen based patch covering the whole right ventricle of pigs, the cells expressing phospho-histone 3 (PH3) still proliferated and were in the process of differentiation toward actinin+ cardiomyocytes within the patch two months after the graft (Fig 1B). However, most of cells migrated into the myocardium while differentiating into cardiomyocytes expressing the human nuclear antigen KU80 and fused MLC2vGFP protein within the sarcomeres. Migration was likely accompanied with a degradation of fibrosis allowed by expression of metalloproteases (i.e. MMP1 and TIMP1) by the CPC (Fig. S2). Interestingly, pig myocytes surrounding the human cardiomyocytes expressed NKX2.5, a transcription factor not any longer expressed in adult myocytes (Fig 1C,D).

We next investigated the effect of the graft of human CPC on the extent of fibrosis of the right ventricle. Pig hearts grafted with a cell-free patch still featured extended interstitial fibrosis as revealed by Sirius red staining (Fig 1D). In contrast, pig hearts grafted with CPC-cellularized patches featured a restricted or no longer fibrosis (Fig 1D).

To further evaluate the reversal in the extent of fibrosis in human CPC-grafted right ventricle, we carried out RT-QPCR of genes expressed in fibroblasts or myofibroblasts. Expression of both *Col1a2* and *Col3a1* genes was significantly decreased in CPC-grafted hearts when

compared to cell–free patch grafted right ventricle. Periostin (*Postn*) expressed in fibroblasts and smooth muscle actin (*acta2*) expressed in myofibroblasts as well as the pro-fibrotic growth factor *TGFβ* were all downregulated in CPC-grafted right ventricles (Fig 1E).

Five months after surgery, echocardiography revealed in the two groups a similar combined RV overload. A significant thickening of the RV free wall secondary to a moderate but significant pulmonary stenosis reflected a barometric overload, associated with a pronounced RV dilatation (volumetric overload) assessed by increased RV/LV ratio, indexed diastolic diameter and both end-diastolic and end-systolic areas, following a severe pulmonary regurgitation (table 1, Fig.2). Echocardiographic standard parameters such as indexed TAPSE and peak systolic velocity of S'wave, as well as myocardial strain measures, significantly decreased to the same extent in the two groups; these results showed an alteration of both global RV function and myocardial contractility. Two months after patch delivery, indexed RV diameter significantly decreased in the CPC group whereas it increased in cell-free group. The free wall thickness significantly increased in the CPC group compared to cell-free group. These results suggest that the RV adaptation to the overload was maintained. The global RV function was maintained in the CPC group while it decreased in the cell-free group. Furthermore, the myocardial contractility specifically assessed by free wall strain significantly improved in the CPC group in contrast to cell-free group in which it kept decreasing. Then, functional characteristics and contractility parameters differently evolved after either with or without cardiac progenitors (Fig 2).

This intriguing observation led us to further investigate the phenotype of pig myocytes surrounding the human MLC2vGFP+ cardiomyocytes within the heart. Measurement of the size of sarcomeres revealed significantly shorter fetal like sarcomeres in pig myocytes neighbor of human cardiomyocytes than myocytes away from this area. Human myocytes also featured short fetal-like sarcomeres as expected from their still immature phenotype (Fig 3A,B). Aurora B staining and localization in the midbodies showed that the cells with short sarcomeres still proliferated (Fig 3C). WGA staining revealed that pig cells with short sarcomeres 1.43 ± 0.035 μm were also shorter (52.7 ± 4.5 μm), than adult pig myocytes (100 ± 5.6 μm, sarcomere of 2.38 ± 0.043 μm) (Figure S3)

As adult cardiomyocytes do not reenter the cell cycle, we wondered how pig fetal like proliferating myocytes could have been generated around grafted human cardiomyocytes. We thus raised the hypothesis that pig myocytes could have de-differentiated and re-differentiated following reactivation of an embryonic genetic program. We thus looked for one of the major

markers of pluripotent naïve stem cells, namely Oct4. Figure 3E reveals that some pig myocytes of CPC-grafted RV but not of cell-free patch grafted RV expressed OCT4 (Fig 4A). OCT4 was localized into the nucleus, thus likely to be transcriptionally active (Fig 4A, inset). A large view of a right ventricular section revealed many clusters of OCT4+ cells (Fig 4B). Some cells also expressed NFκB or both nuclear OCT4 and peri-nuclear NFκB (Fig 4C). An anti-Nanog antibody failed to mark OCT4+ cells (data not shown).

We thus reasoned that graft of CPC and their migration within the myocardium could trigger a local and restricted inflammation. Cytokines released within the environment could in principle activate NFκB pathway in either or both cardiac fibroblasts and cardiomyocytes. To test such a hypothesis, cardiac human fibroblasts were transfected with *p65/NFκB* cDNA. Ten days later NFκB+ cells expressed OCT4 (Fig S4A). Second neonatal post-mitotic mouse day 7 cardiomyocytes in primary culture were chosen for their capability to be transfected. *p65/NFκB* cDNA was transfected in the myocytes. One week later, colonies of OCT4+ cells were observed in the culture (Fig S4B). These dedifferentiated cells re-differentiated into cardiomyocytes as indicated by re-expression of actinin set in still immature sarcomeres (Fig S3B). Interleukin 6 as well as oncostatin-M activation of myocytes also led to a dose dependent reprogramming in OCT4+ cells although cell programming was not back to pluripotent stemness as nanog was not expressed in these treated cells (Fig S5) .

We next hypothesized that a local inflammation should be mediated by resident immune cells. Macrophages have been involved in tissue regeneration (*17*) in many non-mammalian organisms. They are part of cardiac resident immune cells including in heart (*18*). We thus tested the presence of macrophages in pig hearts. While a few macrophages could be found in RV grafted with cell-free patches (Fig 5A), pig hearts grafted with CPC revealed the presence of many iba1+ macrophages and more specifically around the graft of human MLC2vGFP myocytes (Fig 5B,C). The immune cells were adherent to pig cardiomyocytes (Fig 5B) and 3D- reconstruction of a z-stack of images even shows that they are integrated within the cardiac fibers (inset Figure 5B) allowing for a close interaction and dialog with the myocytes.

Single cells were isolated from right ventricle two weeks after the graft of human CPCs. More specifically sus-epicardial cells were dissociated and subjected to single-cell RNA-seq. Figure 6 revealed the different cell types included in the isolated cells. The endothelial/endocardial cells were the most represented cells types as expected in adult heart (*19*) (Fig 6A,B). These cells were composed of both proliferative and p21+ (*cdkn1a+)* cells. More interestingly, we found a population of immature cardiomyocytes still expressing cardiac transcription factors such as *Nkx 2-5, Gata4, Mef2c* as well as *Actn2* and early genes such as *Bves*, *Tcea3*, *Fhod3 (20)* (cluster 6) no more expressed in mature cardiomyocytes (cluster 2). Besides smooth muscle cells and ATP-binding cassette sub-family c member 9 (*abbc9*)+ pericytes, we also identified cells expressing fibroblastic markers *PdgfRα, serpinf1, Col3a1, Col1a1,* and high level of lumican *(Lum)* (Fig 6A), a gene highly expressed in blastema cells of axolotl (*21*). Two populations of macrophages(*18*) including *Lyve1+, CD163+, CCR2-* resident cardiac macrophages and *Aif1+, Plek+, Tyropbp+* were also present (Fig 6A,B,C) and were sub-clustered in clusters 9 and 10 (Fig 6D).

Here, we demonstrate that the epicardial delivery of cardiac progenitors in pigs with right ventricular failure, triggers reprogramming of pig cardiomyocytes into Oct4+ cells that re-differentiate into ventricular myocytes and regenerate the myocardium. The cells allow fibrosis to be reversed and improve index of contractility of the ventricle following a true myocardial regeneration process (Fig 6).

The pigs used in this study were 6-7 months old at the time of cell grafting thus far from the regenerative post-birth windows (*22, 23*). Furthermore the *in-vivo* myocyte reprogramming was triggered by a cell-cell interactions and endogenous cytokines without delivery of any pluripotency genes previously reported to trigger the same process (*24*).

The role of inflammation and specifically macrophages in tissue regeneration is not entirely new (*25, 26*) but the cell and molecular mechanisms have not been well documented specifically for myocardial regeneration. It has furthermore never been directly associated with a cell therapy approach or involved in a process of *in vivo* cell reprogramming.

We now show that the primary event and the trigger of myocardial regeneration is the migration of cardiac progenitor cells from the epicardial patch towards the myocardium. The cells that underwent epithelial-to-mesenchymal transition earlier in the process of differentiation, an event required for their migration recapitulating the embryonic scenario indeed have the proteolytic equipment (Fig S2) to degrade the proteins of the extracellular matrix. They thus make their own path toward the myocardium through the interstitial fibrosis

while differentiating (Fig 1). The degraded proteins thus add to the damaged associated molecular patterns (DAMP) likely constituted of components of dead myocytes or released by them such as ATP. This triggers an inflammatory process as revealed by the presence of NFκB expressing cells (Fig 3, Fig 6) still present two months after cell delivery. Interestingly many cells including fibroblasts and cardiomyocytes feature DAMP-sensing receptors (27) making the scenario more than likely.

The activated NFκB pathway in cardiomyocytes triggers a re-expression of the pluripotency factor Oct4 as revealed by immunofluorescence of CPC-grafted right ventricular sections (Fig 3). That NFκB is sufficient to induce Oct4 and to reprogram both cardiac fibroblasts and myocytes was revealed by our in vitro cell transfection assays (Fig S4) and as we previously reported for valvular cells (28). These OCT4$^+$ cells look similar to blastema cells (Fig 6) found in regenerative species such as amphibians (29).

Interestingly, the OCT4+ cells are capable to re-differentiate into myocytes both *in-vivo* and *in-vitro* (Fig 3 and S4) likely because of their environment and their epigenetic memory that they retained as blastemal cells[26].

The immune cell involved is likely to be a macrophage often reported as a pro-regenerative and tissue repair cell. We found tow populations of macrophages in our single cell-RNA seq analysis (Fig 6) and Iba1+ macrophages attached to cardiomyocytes and clustered in RV grafted with CPC around the graft, which suggests their activated state (Fig 4). They thus have a privileged location to interact and dialog with cardiomyocytes and in turn to secrete their cytokines in their vicinity. Which macrophage plays that role is still not yet known under our experimental situation. We can however surmise that it could be a CCR2$^-$, *Lyve1+*, *CD163+* macrophage of embryonic origin known to play a role in pediatric heart regeneration (18, 26, 30). Lavine et al (26) have reported that embryonic macrophages are replaced by pro-inflammatory monocytes in adult post myocardial infarcted (MI) mouse hearts. However our pig model of RV failure with interstitial fibrosis is different from a mouse MI model with a scar. Furthermore Pig macrophages are transcriptionally more close to human, than mouse immune cells (31). Local activation of CCR2$^-$ *Lyve1+*, *CD163+* macrophages within the interstitial fibrosis is still very likely and experiments of spatial transcriptomics and proteomics should clear up this issue. Interestingly, activation of macrophages could help in clearing the fibrosis by a facilitated infiltration within proliferating new cardiac myocytes (32). Such a proliferative process for new cardiac progenitors emerging from a blastemal

could also be boosted by many p21+ senescent cells that we identified in our single cell-RNA seq dataset (Fig 6) as found during axolotl regeneration process (*33*).

How NFκB and cardiac inflammasome do reprogram pig myocytes without triggering an adverse inflammatory process remains to be elucidated. The location and the intimate dialog of resident macrophages with myocytes could in part answer the question. Furthermore, NFκB acts as a pioneer factor and likely requires another transcription factor to bind super-enhancer on *Oct4* gene regulatory regions (*34*). It acts as a dosage dependent manner and its target-genes depend upon the frequency and amplitude of its intracellular oscillations (*34, 35*). Thus a time-dependent fine tuning regulation of activation of NFκB likely allows for cell reprogramming *versus* inflammation and fibrosis (Fig.6).

Microglia (i.e macrophages) that are also from embryonic origin(*36*) have been recently reported to promote adult brain repair as well as liver regeneration, an event mediated by an IL6 pro-regenerative pathway(*37, 38*) even if the mechanism of the regeneration was not investigated.

Dedifferentiation or even reverse differentiation into stem cells as reported herein could be an efficient means to organ regeneration as previously reported and debated(*39, 40*). Oncostatin has been suggested to dedifferentiate cardiomyocytes (*41, 42*) as we found (Fig S5). Furthermore, the cytokine inhibits TGFβ-dependent fibrosis (*43*). Dedifferentiation or even reverse differentiation is as more important and even facilitated for organs such as the hearts that lack stem cells, which could compete with such a process (*39*). That dedifferentiation Thus such a macrophage-induced cell reprogramming or reverse differentiation toward a blastemal-like stage could be a general cell mechanism to be explored in regenerative medicine.

ACKNOWLEGMENTS

We are very grateful to de Federation Francaise de Cardiologie (To VL, MP) and The Leducq Foundation which funded this work (SHAPEHEART network of excellence) and for generously awarding us for cell imaging facility (MP "Equipement de Recherche et Plateformes Technologiques" (ERPT)). We thank Drs Serge Van de Pavert and Marc Bajenoff (Centre Immunologie de Marseille-Luminy) for fruitful and helpful discussions.

Regulations

All experiments were carried out according to the European Community guiding principles in the care and use of animals (2010/63/UE, 22 September 2010), the local Ethics Committee guidelines and the French decree n°2013-118 on the protection of animals used for scientific purposes (JORF n°0032, 7 February 2013 p2199, text n°24). Authorization to perform animal experiments according to this decree was obtained from the Ministère Français de l'Agriculture, de l'Agroalimentaire et de la Forêt (agreement N° B92-019-01).

REFERENCES

1. J. I. Hoffman, S. Kaplan, The incidence of congenital heart disease. *J Am Coll Cardiol* **39**, 1890-1900 (2002).
2. L. Lopez *et al.*, Unnatural history of the right ventricle in patients with congenitally malformed hearts. *Cardiol Young* **20 Suppl 3**, 107-112 (2010).
3. G. P. Diller *et al.*, Lifespan Perspective on Congenital Heart Disease Research: JACC State-of-the-Art Review. *J Am Coll Cardiol* **77**, 2219-2235 (2021).
4. P. M. Moons, A, Born to Age: when adult congenital heart disease converges with Geroscience. *JACC: advances* **1**, &-12 (2022).
5. F. Wang *et al.*, Heart failure risk predictions in adult patients with congenital heart disease: a systematic review. *Heart* **105**, 1661-1669 (2019).
6. K. Norozi *et al.*, Incidence and risk distribution of heart failure in adolescents and adults with congenital heart disease after cardiac surgery. *Am J Cardiol* **97**, 1238-1243 (2006).
7. A. M. Garcia, J. T. Beatty, S. J. Nakano, Heart failure in single right ventricle congenital heart disease: physiological and molecular considerations. *Am J Physiol Heart Circ Physiol* **318**, H947-H965 (2020).
8. S. Reddy, D. Bernstein, Molecular Mechanisms of Right Ventricular Failure. *Circulation* **132**, 1734-1742 (2015).
9. S. Cohen, A. Marelli, Evolving heart transplantation across the lifespan: A growing population of adults with congenital heart disease. *Arch Cardiovasc Dis* **109**, 511-513 (2016).
10. C. E. Murry, W. R. MacLellan, Stem cells and the heart-the road ahead. *Science* **367**, 854-855 (2020).
11. M. Abdullah *et al.*, Stem Cell Therapy in Single-Ventricle Physiology: Recent Progress and Future Directions. *Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu* **24**, 67-76 (2021).
12. G. J. Bittle *et al.*, Stem Cell Therapy for Hypoplastic Left Heart Syndrome: Mechanism, Clinical Application, and Future Directions. *Circ Res* **123**, 288-300 (2018).
13. V. Lambert *et al.*, Right ventricular failure secondary to chronic overload in congenital heart disease: an experimental model for therapeutic innovation. *The Journal of thoracic and cardiovascular surgery* **139**, 1197-1204, 1204 e1191 (2010).
14. C. Grey, A. Mery, M. Puceat, Fine-tuning in Ca2+ homeostasis underlies progression of cardiomyopathy in myocytes derived from genetically modified embryonic stem cells. *Human molecular genetics* **14**, 1367-1377 (2005).
15. I. Jebeniani, S. Ding, M. Puceat, Improved Protocol for Cardiac Differentiation and Maturation of Pluripotent Stem Cells. *Methods Mol Biol* **1994**, 71-77 (2019).
16. G. Blin, T. Neri, S. Stefanovic, M. Puceat, Human embryonic and induced pluripotent stem cells in basic and clinical research in cardiology. *Current stem cell research & therapy* **5**, 215-226 (2010).
17. T. A. Wynn, A. Chawla, J. W. Pollard, Macrophage biology in development, homeostasis and disease. *Nature* **496**, 445-455 (2013).
18. G. Bajpai *et al.*, The human heart contains distinct macrophage subsets with divergent origins and functions. *Nat Med* **24**, 1234-1245 (2018).
19. I. A. Pinto AR, Ivey MJ, Kuwabara JT, D'Antoni ML, Debuque R, Chandran A, Wang L, Arora K, Rosenthal NA, Tallquist MD, Revisiting Cardiac Cellular Composition. *Circ.res.* **118** 400-409 (2016).
20. S. S. Xu XQ, Sun W, Zweigerdt R., Global expression profile of highly enriched cardiomyocytes derived from human embryonic stem cells. *Stem cells* **27**, 2163-2174 (2009).
21. D. G. Leigh ND, Johnson K, Mariano R, Oshiro R, Wong AY, Bryant DM, Miller BM, Ratner A, Chen A, Ye WW, Haas BJ, Whited JL, Transcriptomic landscape of the blastema niche in regenerating adult axolotl limbs at single-cell resolution. *Nat Commun* **9**, (2018).

22.	N. Velayutham *et al.*, Cardiomyocyte cell cycling, maturation, and growth by multinucleation in postnatal swine. *J Mol Cell Cardiol* **146**, 95-108 (2020).

23.	N. Velayutham, K. E. Yutzey, Porcine Models of Heart Regeneration. *J Cardiovasc Dev Dis* **9**, (2022).

24.	Y. P. Chen *et al.*, Reversible reprogramming of cardiomyocytes to a fetal state drives heart regeneration in mice. *Science* **373**, 1537-+ (2021).

25.	J. P. Cooke, Inflammation and Its Role in Regeneration and Repair. *Circ Res* **124**, 1166-1168 (2019).

26.	K. J. Lavine *et al.*, Distinct macrophage lineages contribute to disparate patterns of cardiac recovery and remodeling in the neonatal and adult heart. *Proc Natl Acad Sci U S A* **111**, 16029-16034 (2014).

27.	T. Gong, L. Liu, W. Jiang, R. Zhou, DAMP-sensing receptors in sterile inflammation and inflammatory diseases. *Nat Rev Immunol* **20**, 95-112 (2020).

28.	E. J. Farrar *et al.*, OCT4-mediated inflammation induces cell reprogramming at the origin of cardiac valve development and calcification. *Sci Adv* **7**, eabf7910 (2021).

29.	J. Ha *et al.*, Intermediate cells of in vitro cellular reprogramming and in vivo tissue regeneration require desmoplakin. *Sci Adv* **8**, eabk1239 (2022).

30.	S. Epelman *et al.*, Embryonic and Adult-Derived Resident Cardiac Macrophages Are Maintained through Distinct Mechanisms at Steady State and during Inflammation. *Immunity* **40**, 91-104 (2014).

31.	R. Kapetanovic *et al.*, The impact of breed and tissue compartment on the response of pig macrophages to lipopolysaccharide. *BMC Genomics* **14**, 581 (2013).

32.	E. S. Akhmanova M, Krueger D, Gyoergy A, Guarda M, Vlasov M, Vlasov F, Akopian A, Ratheesh A, De Renzis S, Siekhaus DE., Cell division in tissues enables macrophage infiltration. *Science* **376**, 394-396 (2022).

33.	W. H. Yu Q, Pasquini G, Pal Singh S, Lachnit M, Oliveira CR, León-Periñán D, Petzold A, Kesavan P, Subiran Adrados C, Garteizgogeascoa I, Knapp D, Wagner A, Bernardos A, Alfonso M, Nadar G, Graf AM, Troyanovskiy KE, Dahl A, Busskamp V, Martínez-Máñez R, Yun MH, Cellular senescence promotes progenitor cell expansion during axolotl limb regeneration. *Dev Cell* **58**, 2416-2427.

34.	H. Michida *et al.*, The Number of Transcription Factors at an Enhancer Determines Switch-like Gene Expression. *Cell Rep* **31**, 107724 (2020).

35.	Q. J. Cheng *et al.*, NF-kappaB dynamics determine the stimulus specificity of epigenomic reprogramming in macrophages. *Science* **372**, 1349-1353 (2021).

36.	F. Ginhoux *et al.*, Fate mapping analysis reveals that adult microglia derive from primitive macrophages. *Science* **330**, 841-845 (2010).

37.	E. F. Willis *et al.*, Repopulating Microglia Promote Brain Repair in an IL-6-Dependent Manner. *Cell* **180**, 833-+ (2020).

38.	L. Li *et al.*, Kupffer-cell-derived IL-6 is repurposed for hepatocyte dedifferentiation via activating progenitor genes from injury-specific enhancers. *Cell Stem Cell* **30**, 283-299 e289 (2023).

39.	P. R. Tata *et al.*, Dedifferentiation of committed epithelial cells into stem cells in vivo. *Nature* **503**, 218-223 (2013).

40.	R. A. Shivdasani, H. Clevers, F. J. de Sauvage, Tissue regeneration: Reserve or reverse? *Science* **371**, 784-786 (2021).

41.	T. Kubin *et al.*, Oncostatin M is a major mediator of cardiomyocyte dedifferentiation and remodeling. *Cell Stem Cell* **9**, 420-432 (2011).

42.	H. Lorchner *et al.*, Myocardial healing requires Reg3beta-dependent accumulation of macrophages in the ischemic heart. *Nat Med* **21**, 353-362 (2015).

43.	H. Abe *et al.*, Macrophage hypoxia signaling regulates cardiac fibrosis via Oncostatin M. *Nat Commun* **10**, 2824 (2019).

Fig. 1: Human ES cell-derived Nkx2.5+ cardiac progenitors migrate, differentiate within the RV myocardium and induce regression of fibrosis (**A**) human ES cell-derived Nkx2.5+ cardiac progenitors sorted using an anti-SSEA1 antibody (**B**) cells proliferate (PH3+) within the patch (**C**) migrate into and differentiate into clustered human KU80+ (light blue indicated by arrow) MLC2VGFP+ cardiomyocytes (**D**) Fibrosis is regressed in RV grafted with human cardiac progenitors. RV sections from pig grafted with an empty patch (Cell-free patch) or with a patch seeded with human cardiac progenitors (CPC-patch) stained with sirius red. Arrows indicate interstitial fibrosis . (**E**) quantification of fibrosis (**F**) Q-PCR of fibrosis related genes in either RV of pigs grafted with empty (cell-free) patchs or cellularized patchs (CPC patch) n=3 pigs. The images are representative of sections from 5 different pigs **t-Test p<0.01

Figure 2: Functional parameters of pig grafted with cell-free patches (empty) or CPC –patch (cell) before the surgery (surgery), the day of the graft (graft) and at the end point of the experiment (euthanasia). The top graphs reflect the remodeling of the RV and the bottom ones, the contractility. T-test was used to compare two time points or Anova to compare 3 time points *p≤0.05 ** p ≤0.01

A

Nkx2.5
Ku80
Actinin
DNA
>Ku80/DNA
Mlc2vGFP

100µm

10 µm

B

Pig myocytes
Neighbor Pig myocytes
human myocytes

Size of sarcomeres (µm)

***   ***

C

Aurora B

1.4µm

1.5µm

10µm

5µm

Fig 3: Pig myocytes reproliferate in human cardiac progenitor-grated RV. Pig RV sections were stained with anti-Nkx2.5, -Ku80 and -sarcomeric actinin antibodies (A) the inset shows high magnication. Human MLCGFP+ myocytes positive for KU80C: (B) size of sarcomeres. Measured in pig myocytes far or close to human myocytes in 3 separate hearts. (C) cells were stained with an anti-auroraB antibody and sarcomeres lenghts measured.

Figure 4: Oct4+reprogrammed myocytes in pig myocardium grafted with human progenitors. Cell- grafted RV sections were stained with anti-Oct4 (green) and anti α-actinin antibodies; Dapi+ nuclei are in red. Arrows point oct4+ yellow cell nuclei (A) and clusters of Oct4+ cells in large view of the cardiac section also stained with anti-Iba1 antibody (purple) (B) . The inset shows a high magnification of cardiomyocytes. Sections were also stained with anti-Oct4 and anti-Nfkb antibodies (C). The inset shows a high magnification of Oct4+/Nfkb+ cells.The figures are representative of at least 4 different pigs grafted with cellularized patch.

Fig. 5: Presence of macrophages on cardiomyocytes surrounding the graft. Macrophages (Iba1+) staining in RV section of pigs grafted with cell-free patch (**A**) or CPC- patch (**B**) Yellow arrows point to macrophages. (**C**) Immunofluorescence anti-Iba1 on RV section of pigs grafted with CPC-patches within the graft area (**D**) high magnification of Iba1+ macrophage on cardiac fibers. The right inset shows a 3D image reconstruction of the image revealing the position of the macrophage within the fiber.

Figure 6 : Single cell analysis of sus-epicardial cells from a pig heart grafted with human cardiac progenitor cells. (A) Heatmap **(B)** UMAP **(C)** panel plot showing genes specific of cell types **(D)** Violin plots of macrophages EC endothelial cells; SMC smooth muscle cells

Figure 7 : graphical summary of the cell reprogramming process